The promoter doesn't specify whether he was compensated for the campaign. However, Crown equity admitted that it might sell securities during the advertising period if paid in stock.
CYTR has been in a slight upward trend since the start of October. The stock hit a 52-week low at $0.30 at the beginning of the month and since then has been going up.
On the last trading session, CYTR at last broke the resistance at $0.35 after opening at $0.36 and hitting an intraday high at $0.4. However, at the end of the day CYTR lost the initial impetus and closed the session exactly at the former resistance.
On the last session, a noticeable surge in the trading volume was also noticed. The number of traded shares hit 3.797 million shares which exceeds four times the 3-month daily average.
In summary, CYTR could leave the boundaries of the trading range even though it had the trade alert from Crown Equity and a press release, which announced favorable result from the ongoing clinical trial, as a back up.
The question is whether bulls will have enough power to withstand the bearish pressure in CYTR stock in the forthcoming sessions.
Cytrx corporation seems like an interesting stock.
ReplyDelete